Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | XBP1 | P17861 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977690 | 0.76 | SMN1; SMN2 (0.71) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2184782 | 0.76 | SMN1; SMN2 (0.71) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL9795719 | 0.75 | TP53 (0.51) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL11754668 | 0.74 | TP53 (0.74) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10382109 | 0.74 | MAPT (0.54) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19639788 | 0.74 | ALDH1A1 (0.57) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Fluometuron SCHEMBL29598187 | 0.73 | TP53 (1.00) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Fluometuron SCHEMBL1701226 | 0.73 | TP53 (1.00) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Fluometuron SCHEMBL67252 | 0.73 | TP53 (1.00) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL9738365 | 0.72 | MAPT (0.53) | TP53SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| WO-2017207433-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-01 | — | — | WO | disclosed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342056-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | TP53 3547/4885SMN1; SMN2 646/4885MEN1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.